RI
RTW Investments Portfolio holdings
AUM
$7.02B
This Quarter Return
+4.78%
1 Year Return
+28.16%
3 Year Return
+245.48%
5 Year Return
+425.65%
10 Year Return
+5,642.23%
AUM
$599M
AUM Growth
+$599M
(+4.3%)
Cap. Flow
+$49.8M
Cap. Flow
% of AUM
8.31%
Top 10 Holdings %
Top 10 Hldgs %
69.44%
Holding
34
New
7
Increased
17
Reduced
7
Closed
2
Top Buys
| 1 |
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
|
$25.9M |
| 2 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
$22.6M |
| 3 |
ACHN
Achillion Pharmaceuticals, Inc.
ACHN
|
$16.4M |
| 4 |
Edwards Lifesciences
EW
|
$13.9M |
| 5 |
PTC Therapeutics
PTCT
|
$10.6M |
Top Sells
| 1 |
Alnylam Pharmaceuticals
ALNY
|
$33.6M |
| 2 |
AVXS
AveXis, Inc. Common Stock
AVXS
|
$20.6M |
| 3 |
BLUE
bluebird bio
BLUE
|
$14.3M |
| 4 |
OXFD
Oxford Immunotec Global PLC Ordinary Shares
OXFD
|
$9.17M |
| 5 |
FSTX
F-star Therapeutics, Inc. Common Stock
FSTX
|
$4.2M |
Sector Composition
| 1 | Healthcare | 90.11% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
PTC Therapeutics
PTCT
$3.92B
| $68.9M | 11.5% | 4,130,115 +634,972 | +18% | +$10.6M |
|
2
Regenxbio
RGNX
$451M
| $51.9M | 8.66% | 1,561,210 +22,205 | +1% | +$738K |
|
3
Bristol-Myers Squibb
BMY
$96B
| $51.4M | 8.59% | 839,452 +11,940 | +1% | +$732K |
|
|
4
Alnylam Pharmaceuticals
ALNY
$58.5B
| $45.6M | 7.61% | 358,774 -264,564 | -42% | -$33.6M |
|
|
DRNA
5
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $44.1M | 7.37% | 5,035,662 +2,956,671 | +142% | +$25.9M |
|
|
ACHN
6
DELISTED
Achillion Pharmaceuticals, Inc.
ACHN
| $39M | 6.51% | 13,546,902 +5,707,136 | +73% | +$16.4M |
|
|
LJPC
7
DELISTED
La Jolla Pharmaceutical Company
LJPC
| $34.2M | 5.71% | 1,063,170 +18,863 | +2% | +$607K |
|
|
AVXS
8
DELISTED
AveXis, Inc. Common Stock
AVXS
| $31.1M | 5.2% | 281,242 -186,425 | -40% | -$20.6M |
|
9
Arbutus Biopharma
ABUS
$711M
| $26M | 4.34% | 5,151,615 -114,665 | -2% | -$579K |
|
|
GBT
10
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $23.7M | 3.95% | 601,683 +575,373 | +2,187% | +$22.6M |
|
11
OraSure Technologies
OSUR
$242M
| $16.6M | 2.77% | 878,452 +342,745 | +64% | +$6.46M |
|
12
BioCryst Pharmaceuticals
BCRX
$1.74B
| $16.6M | 2.76% | 3,372,674 +47,969 | +1% | +$236K |
|
|
CORI
13
DELISTED
Corium International, Inc.
CORI
| $16.3M | 2.73% | 1,699,653 +24,174 | +1% | +$232K |
|
|
AGEN
14
Agenus
AGEN
$133M
| $14.1M | 2.36% | 4,329,816 +111,296 | +3% | +$363K |
|
|
15
Edwards Lifesciences
EW
$47.8B
| $13.9M | 2.31% | +123,000 | New | +$13.9M |
|
|
VRAY
16
DELISTED
ViewRay, Inc.
VRAY
| $12.5M | 2.08% | 1,348,210 +327,748 | +32% | +$3.03M |
|
|
MYOK
17
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $10.8M | 1.81% | 257,663 +3,701 | +1% | +$156K |
|
18
Masimo
MASI
$7.59B
| $10.3M | 1.71% | 120,900 | – | – |
|
19
Atara Biotherapeutics
ATRA
$84.6M
| $10.1M | 1.68% | 556,118 -99,900 | -15% | -$1.81M |
|
|
KA
20
DELISTED
Kineta, Inc. Common Stock
KA
| $8.75M | 1.46% | +1,500,000 | New | +$8.75M |
|
|
VIVE
21
DELISTED
VIVEVE MED INC
VIVE
| $8.32M | 1.39% | 1,672,998 +199,970 | +14% | +$994K |
|
22
uniQure
QURE
$896M
| $7.91M | 1.32% | +403,524 | New | +$7.91M |
|
23
Vericel Corp
VCEL
$1.83B
| $7.11M | 1.19% | +1,304,801 | New | +$7.11M |
|
|
ODT
24
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
| $6.77M | 1.13% | +297,555 | New | +$6.77M |
|
25
Tactile Systems Technology
TCMD
$297M
| $6.1M | 1.02% | 210,366 -142,850 | -40% | -$4.14M |
|